HODGKIN LYMPHOMA. A COMPREHENSIVE OVERVIEW. 3RD EDITION

Part I: Epidemiology and Pathogenesis
• Epidemiology of Hodgkin Lymphoma
• The role of viruses in the genesis of Hodgkin Lymphoma
• Pathology and molecular pathology of Hodgkin Lymphoma
• Microenvironment, cross-talk and immune escape mechanisms
•What will we learn from Genomics and Proteomics in Hodgkin Lymphoma?
Part II: Diagnosis and first-line treatment
• Clinical evaluation
• Functional imaging in Hodgkin Lymphoma
• Prognostic factors. - Principles of Radiation Therapy for Hodgkin Lymphoma
• Principles of chemotherapy in Hodgkin Lymphoma
• Treatment of early favorable Hodgkin Lymphoma
• Treatment of early unfavorable Hodgkin Lymphoma
• Treatment of advanced-stage Hodgkin Lymphoma
• Optimizing Decision Making in HL
Part III: Special clinical situations
• Paediatric/adolescent Hodgkin Lymphoma
• The management of elderly patients with Hodgkin Lymphoma
• Nodular Lymphocyte-Predominant Hodgkin Lymphoma
• The management of Hodgkin Lymphoma during pregnancy
• The management of HIV-Hodgkin Lymphoma
Part IV: Relapsed and refractory disease
• Relapsed and refractory Hodgkin Lymphoma
• Allogeneic transplantation for relapsed Hodgkin Lymphoma
• Targeting CD30 in Patients with Hodgkin Lymphoma
• Hodgkin Lymphoma and PD-1 blockade
• Other new agents for Hodgkin Lymphoma
Part V: Survivorship
• Quality of Life in Hodgkin lymphoma
• Second malignancy risk after treatment of Hodgkin Lymphoma
• Cardiovascular and pulmonary late effects
• Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients
• Fatigue.

This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

Features
• Examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma
• Reviews the emerging individually tailored treatment strategies
• Covers pathogenesis, clinical evaluation, imaging diagnosis, staging, prognostic factors, and survivorship